Edition:
India

Profile: Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

16.02USD
18 Apr 2019
Change (% chg)

$0.41 (+2.63%)
Prev Close
$15.61
Open
$15.81
Day's High
$16.05
Day's Low
$15.14
Volume
184,367
Avg. Vol
256,310
52-wk High
$19.11
52-wk Low
$8.35

Fate Therapeutics, Inc. (Fate Therapeutics), incorporated on April 27, 2007, is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

The Company's clinical program, ProTmune, is a programmed immuno-regulatory cell therapy consisting of donor-sourced mobilized peripheral blood cells, which have been modulated using two small molecules, for the prevention of acute graft-versus-host disease (GvHD) and cytomegalovirus (CMV) infection in immunocompromised patients undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is conducting Phase I/II clinical trial of ProTmune.

The Company's preclinical programs include NK- and T-cell cancer immunotherapies, including off-the-shelf therapies derived from engineered induced pluripotent cells (denoted as an iNK Cell Therapy and an iT Cell Therapy), and CD34+ cell immuno-regulatory therapy to suppress aberrant auto-reactive effector cells for autoimmune diseases. Adaptive NK Cell Therapy is indicated for the treatment of solid tumors. Its Programmed iNK Cell Therapy and Programmed iT Cell Therapy are indicated for hematologic/solid tumors. The Company is engaged in conducting preclinical trials for Programmed CD34+ Cell Therapy, Adaptive NK Cell Therapy, Programmed iNK Cell Therapy and Programmed iT Cell Therapy.

Company Address

Fate Therapeutics Inc

3535 General Atomics Ct Ste 200
SAN DIEGO   CA   92121-1140
P: +1858.8751803
F: +1302.6365454

Company Web Links